Jove
Visualize
Contact Us

Related Experiment Videos

Diabetic dyslipidaemia: from basic research to clinical practice.

M-R Taskinen1

  • 1Department of Medicine, Division of Cardiology, University of Helsinki, Helsinki, Finland. mataskin@helsinki.fi

Diabetologia
|May 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes.

Journal of internal medicine·2021
Same author

Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.

Journal of internal medicine·2019
Same author

Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate - Authors' response.

Journal of internal medicine·2019
Same author

Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.

Journal of internal medicine·2019
Same author

Metabolic syndrome associates with left atrial dysfunction.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.

Journal of internal medicine·2017
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Diabetic dyslipidaemia involves increased triglyceride-rich lipoproteins (TRLs) and atherogenic lipid changes. Understanding VLDL 1 particle overproduction mechanisms in Type 2 diabetes is key to developing new treatments.

Area of Science:

  • Lipid metabolism and cardiovascular disease
  • Endocrinology and metabolic disorders
  • Molecular biology of lipoprotein assembly

Background:

  • Diabetic dyslipidaemia presents complex lipoprotein alterations beyond standard lipid measures.
  • Heterogeneity within VLDL, LDL, and HDL particles reveals specific diabetic dyslipidaemia perturbations.
  • The atherogenic lipid triad, including increased large VLDL 1, is linked to Type 2 diabetes.

Purpose of the Study:

  • To elucidate the mechanisms driving the overproduction of VLDL 1 particles in diabetic dyslipidaemia.
  • To investigate how the liver regulates triglyceride incorporation into VLDL particles (VLDL 1 vs. VLDL 2).
  • To identify key molecular players and potential therapeutic targets in diabetic dyslipidaemia.

Main Methods:

Related Experiment Videos

  • Review of current evidence on VLDL assembly and secretion pathways.
  • Analysis of the roles of insulin signaling, SREBP-1C, and apo B 100 stabilization.
  • Examination of transcription factors (PPARs, SREBP-1, LXRs) in hepatic lipid assembly.

    • Main Results:

    • Low insulin signaling, up-regulated SREBP-1C, and excess polar molecules in hepatocytes contribute to VLDL assembly.
    • These factors may explain VLDL apo B overproduction in Type 2 diabetes.
    • Insulin's ability to suppress VLDL 1 apo B production is altered in Type 2 diabetes.

    Conclusions:

    • Understanding VLDL 1 overproduction mechanisms is crucial for managing diabetic dyslipidaemia.
    • Transcription factors like PPARs, SREBP-1, and LXRs are key regulators of hepatic lipid assembly.
    • These factors represent promising targets for novel therapeutic strategies against diabetic dyslipidaemia.